US Patent

US10022379 — DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation

Method of Use · Assigned to Boehringer Ingelheim International GmbH · Expires 2029-04-02 · 3y remaining

Vulnerability score 75/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects pharmaceutical compositions that combine a DPP-4 inhibitor with another antidiabetic agent, and methods for preparing and using these combinations.

USPTO Abstract

The present invention relates to pharmaceutical compositions comprising fixed dose combinations of a DPP-4 inhibitor drug and a partner drug, processes for the preparation thereof, and their use to treat certain diseases.

Drugs covered by this patent

Jardiance (empagliflozin) · Boehringer Ingelheim
Tradjenta (LINAGLIPTIN) · Boehringer Ingelheim

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-2732`	—	Jardiance
`U-2732`	—	Jardiance
`U-2732`	—	Jardiance
`U-2339`	—	Tradjenta
`U-2339`	—	Tradjenta
`U-2339`	—	Tradjenta
`U-2339`	—	Tradjenta
`U-2732`	—	Jardiance
`U-2339`	—	Tradjenta

Patent Metadata

Patent number: US10022379
Jurisdiction: US
Classification: Method of Use
Expires: 2029-04-02
Drug substance claim: No
Drug product claim: Yes
Assignee: Boehringer Ingelheim International GmbH
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.